Ingevity stock has delivered a strong 61.9% return over the past year, yet its current valuation checks lean toward the shares looking expensive rather than like an obvious bargain.

• Over the last 12 months, Ingevity has returned 61.9%, which puts a spotlight on whether recent gains already reflect the good news in the price.
• Approval of Evotherm P35 in Germany can support confidence in Ingevity's pavement technologies. However, any setback in demand for higher value applications or portfolio execution may weigh on what investors are willing to pay.
• On Simply Wall St's valuation checks, Ingevity only passes 2 out of 6. This suggests the stock does not screen as clearly cheap on the broader measures. See the 2/6 score for detail.

The stock's next move may depend on whether that strong share price performance can be justified by fundamentals that catch up with the valuation.

Is Ingevity Getting Expensive on Sales?

The P/S ratio suits Ingevity because revenue is a cleaner yardstick when earnings and book value metrics are harder to interpret. Right now, Ingevity trades on a P/S of about 2.2x, compared with an industry average of roughly 1.1x and a peer group average near 1.3x. This means the stock changes hands at a clear premium to typical Chemicals stocks on sales.

The fair P/S ratio from the model is around 1.5x, which is lower than where Ingevity currently sits. This indicates the market is paying more per dollar of revenue than this framework suggests is warranted. Despite the positive attention around Evotherm P35 approval in Germany, the current P/S still prices Ingevity ahead of both the modelled fair level and sector benchmarks.

On this P/S multiple, Ingevity stock screens as overvalued relative to both its fair ratio and broader Chemicals peers.

The Ingevity Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Ingevity pick up where this valuation puzzle leaves off by spelling out which assumptions about Ingevity's future growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today's price. Each narrative ties a fair value estimate to a particular mix of potential catalysts and risks, so you can track over time which version of the Ingevity story appears to be taking shape on the Community page.

If you have a number driven view on whether Ingevity's Evotherm P35 approval in Germany and its recent share price strength support today's valuation, share a Narrative on Simply Wall St to set out your case in one place.

It can be a concise way to add your voice on Ingevity, spell out the key drivers you are watching and see how your thesis holds up as new results and news arrive.

Do you think there's more to the story for Ingevity? Head over to our Community to see what others are saying!

The Bottom Line

For Ingevity, the current picture points to a stock that screens as overvalued on sales based on its P/S premium and broader valuation checks. That does not rule out further gains, but it does mean expectations already bake in a lot of optimism around revenue quality and execution. From here, the key question is whether Ingevity can sustain demand in its higher value applications and deliver on its product pipeline strongly enough to convince investors that the current revenue multiple remains justified.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.